In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market
To discuss the current investment environment in cell and gene therapy, the challenges faced, and how Circio adapted to survive the downturn.
Approach:
Company Transition: Circio shifted focus from clinical cancer vaccine programs to a preclinical circular RNA platform due to declining interest in cancer vaccines.
Funding Strategies: The company utilized unconventional financing methods and maintained a low cost base to navigate the funding challenges.
Technology Development: Circio engineered AAV gene therapies using circular RNA to enhance protein expression and reduce toxicity.
Investor Engagement: The company rebuilt investor confidence through strategic partnerships and successful financing rounds.
Key Findings:
Investors are now more cautious and prefer longer funding horizons.
Larger VC rounds are common, with a focus on early-stage technologies.
Circio secured significant funding through innovative financing mechanisms, including a recent NOK 250 million financing round.
Interpretation:
The shift in investor behavior reflects a more cautious approach to funding in the biotech sector, emphasizing long-term viability.
Limitations:
The article does not provide quantitative data on the overall market trends in cell and gene therapy funding.
Specific details on the outcomes of the new circular RNA platform are not fully disclosed, particularly regarding its clinical applications.
Conclusion:
Circio's strategic pivot and innovative financing have positioned it to navigate a challenging investment landscape.
